The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; IMPAC Medical Systems; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; IMPAC Medical Systems; Lilly
 
Nai-Jung Chiang
Honoraria - Bristol Myers Squibb Foundation; Ono Pharmaceutical; PharmaEngine; TTY Biopharm
Consulting or Advisory Role - CStone Pharmaceuticals
 
Jih-hsiang Lee
Consulting or Advisory Role - Lilly O.; Novartis; Takeda
Speakers' Bureau - Novartis; Pfizer
 
Ming-Huang Chen
No Relationships to Disclose
 
Yee Chao
No Relationships to Disclose
 
Wu-Chou Su
Consulting or Advisory Role - Bayer Schering Pharma; Lilly O.; Merck; MSD Oncology
 
Li-Yuan Bai
Honoraria - CStone Pharmaceuticals; Ipsen; Lilly; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - CStone Pharmaceuticals; Zai Lab
Research Funding - Eisai
 
Shang-Yin Wu
Honoraria - Bristol Myers Squibb Foundation; Merck; Merck Sharp & Dohme, MSD
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
 
Yan-Shen Shan
No Relationships to Disclose
 
Chung-Pin Li
No Relationships to Disclose
 
Shang-Hung Chen
No Relationships to Disclose
 
Wei-Pang Chung
No Relationships to Disclose
 
Li-Tzong Chen
Leadership - ScinoPharm
Honoraria - ACT Genomics; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CStone Pharmaceuticals; Ipsen; Lilly; MSD; Ono Pharmaceutical; Onward Therapeutics; Taivex Therapeutics; TTY Biopharm
Research Funding - ACT genomics (Inst); Celgene (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Polaris (Inst); SynCoreBio (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan